$283 Million is the total value of ACUTA CAPITAL PARTNERS, LLC's 47 reported holdings in Q3 2021. The portfolio turnover from Q2 2021 to Q3 2021 was 41.2% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| ISEE | Sell | IVERIC BIO INC | $18,432,000 | +133.7% | 1,135,000 | -9.2% | 6.50% | +106.3% |
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $18,222,000 | -44.8% | 337,500 | -65.8% | 6.43% | -51.3% |
| FULC | Sell | FULCRUM THERAPEUTICS INC | $9,098,000 | +43.7% | 322,500 | -46.6% | 3.21% | +26.9% |
| KURA | Sell | KURA ONCOLOGY INC | $5,467,000 | -25.8% | 291,884 | -17.4% | 1.93% | -34.5% |
| VINC | Sell | VINCERX PHARMA INC | $4,204,000 | -32.3% | 260,000 | -45.7% | 1.48% | -40.3% |
| ATHA | Sell | ATHIRA PHARMA INC | $2,789,000 | -36.2% | 297,362 | -30.4% | 0.98% | -43.7% |
| ACRS | Sell | ACLARIS THERAPEUTICS INC | $2,535,000 | -17.5% | 140,839 | -19.5% | 0.89% | -27.2% |
| APLS | Sell | APELLIS PHARMACEUTICALS INC | $2,488,000 | -75.5% | 75,500 | -53.0% | 0.88% | -78.3% |
| CBIO | Sell | CATALYST BIOSCIENCES INC | $1,500,000 | -49.4% | 365,000 | -46.7% | 0.53% | -55.4% |
| CMRX | Sell | CHIMERIX | $1,300,000 | -68.1% | 210,000 | -58.8% | 0.46% | -71.8% |
| CPRX | Exit | CATALYST PHARMACEUTICALS INC | $0 | – | -329,134 | -100.0% | -0.76% | – |
| Exit | CATABASIS PHARMACEUTICALS IN | $0 | – | -1,173,674 | -100.0% | -0.99% | – | |
| SAGE | Exit | SAGE THERAPEUTICS INC | $0 | – | -50,945 | -100.0% | -1.16% | – |
| AVDL | Exit | AVADEL PHARMACEUTICALS PLCsponsored adr | $0 | – | -561,011 | -100.0% | -1.51% | – |
| ALGS | Exit | ALIGOS THERAPEUTICS INC | $0 | – | -214,254 | -100.0% | -1.75% | – |
| EPIX | Exit | ESSA PHARMA INC | $0 | – | -232,896 | -100.0% | -2.66% | – |
| CLDX | Exit | CELLDEX THERAPEUTICS INC NEWput | $0 | – | -500,000 | -100.0% | -6.68% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-11-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS INC | 24 | Q1 2023 | 21.2% |
| IRIDEX CORP | 20 | Q3 2019 | 8.1% |
| ARROWHEAD PHARMACEUTICALS INC | 20 | Q2 2023 | 7.9% |
| IMMUNOMEDICS INC | 19 | Q3 2020 | 20.6% |
| VERACYTE INC | 19 | Q3 2019 | 10.1% |
| ASCENDIS PHARMA A S | 18 | Q2 2020 | 7.2% |
| XENON PHARMACEUTICALS INC | 18 | Q3 2022 | 4.6% |
| CAS MED SYS PAR $0.004 | 18 | Q1 2019 | 6.4% |
| APELLIS PHARMACEUTICALS INC | 17 | Q3 2023 | 18.4% |
| KURA ONCOLOGY INC. COMMON STOCK | 17 | Q3 2023 | 8.1% |
View ACUTA CAPITAL PARTNERS, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| BCLS Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| Jiya Acquisition Corp.Sold out | February 14, 2023 | 0 | 0.0% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Larimar Therapeutics, Inc.Sold out | February 15, 2022 | 0 | 0.0% |
| CATALYST BIOSCIENCES, INC.Sold out | February 14, 2022 | 0 | 0.0% |
| Aadi Bioscience, Inc. | September 07, 2021 | 1,529,402 | 7.2% |
| Kadmon Holdings, Inc. | February 14, 2020 | 7,373,333 | 4.6% |
| IRIDEX CORPSold out | November 13, 2019 | 0 | 0.0% |
| ASSEMBLY BIOSCIENCES, INC. | February 14, 2019 | 718,500 | 2.8% |
| CAS MEDICAL SYSTEMS INC | February 14, 2019 | 5,263,508 | 18.2% |
View ACUTA CAPITAL PARTNERS, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| SC 13G/A | 2023-02-14 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-15 |
View ACUTA CAPITAL PARTNERS, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.